Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
Date:8/11/2008

XI'AN, China, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that it has signed a major supply agreement with DNP International Co., Inc. of Santa Fe Springs, CA.

Under the terms of the agreement Huifeng is to deliver 62 metric tons of Glucuronolactone, a naturally occurring chemical compound which has become a popular additive to energy drinks, over the next six months to DNP. The total dollar amount of the contract is in excess of USD $1.1 Million.

Huifeng anticipates signing additional bi-annual contracts with DNP upon successful completion of the first agreement.

''Our agreement with DNP further demonstrates the increasing international acceptance of Huifeng products. With quality and consistency as our hallmarks, we are now becoming recognized by major US corporations for the quality and consistency of the products we develop and manufacture,'' stated company CEO Jing'An Wang. ''We are pleased to be making further inroads into the US market and hope to sign similar supply agreements with DNP and other US entities in the near future.''

About Glucuronolactone

Glucuronolactone is a naturally occurring chemical compound produced by the metabolism of glucose in the human liver. It is an important structural component of nearly all connective tissues. The most common usage for Glucuronolactone is in many energy drinks. Because most of these drinks also contain caffeine, Glucuronolactone is included because it is purported to fight fatigue and provide a sense of well-being. According to "The Merck Index" (14th edition) it is also used as detoxicant. (From Wikipedia)

About DNP International

DNP International imports and distributes raw material ingredients to manufacturers in the nutritional
'/>"/>

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
2. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
3. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
4. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
5. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
6. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
7. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
8. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
9. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
10. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
11. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4